These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22015772)

  • 21. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST; Gotlib J
    Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
    Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
    Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
    Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two homogeneous cell-based kinase assays for JAK2 V617F: SureFire pSTAT5 and GeneBLAzer fluorescence resonance energy transfer assays.
    Qian J; Mason JL; Holskin BP; Murray KA; Meyer SL; Ator MA; Angeles TS
    Assay Drug Dev Technol; 2012 Apr; 10(2):212-7. PubMed ID: 22132729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
    Stein BL; Crispino JD; Moliterno AR
    Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Janus kinase 2 inhibitors in myeloproliferative disorders.
    Lucia E; Recchia AG; Gentile M; Bossio S; Vigna E; Mazzone C; Madeo A; Morabito L; Gigliotti V; De Stefano L; Caruso N; Servillo P; Franzese S; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Jan; 20(1):41-59. PubMed ID: 21128825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
    Brasca MG; Gnocchi P; Nesi M; Amboldi N; Avanzi N; Bertrand J; Bindi S; Canevari G; Casero D; Ciomei M; Colombo N; Cribioli S; Fachin G; Felder ER; Galvani A; Isacchi A; Motto I; Panzeri A; Donati D
    Bioorg Med Chem; 2015 May; 23(10):2387-407. PubMed ID: 25882525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-H Arylation in the Formation of a Complex Pyrrolopyridine, the Commercial Synthesis of the Potent JAK2 Inhibitor, BMS-911543.
    Fox RJ; Cuniere NL; Bakrania L; Wei C; Strotman NA; Hay M; Fanfair D; Regens C; Beutner GL; Lawler M; Lobben P; Soumeillant MC; Cohen B; Zhu K; Skliar D; Rosner T; Markwalter CE; Hsiao Y; Tran K; Eastgate MD
    J Org Chem; 2019 Apr; 84(8):4661-4669. PubMed ID: 30388009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib effect on growth and signal transduction in polycythemia vera.
    Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
    Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors.
    Su Q; Ioannidis S; Chuaqui C; Almeida L; Alimzhanov M; Bebernitz G; Bell K; Block M; Howard T; Huang S; Huszar D; Read JA; Rivard Costa C; Shi J; Su M; Ye M; Zinda M
    J Med Chem; 2014 Jan; 57(1):144-58. PubMed ID: 24359159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance.
    Huang SM; Wang A; Greco R; Li Z; Barberis C; Tabart M; Patel V; Schio L; Hurley R; Chen B; Cheng H; Lengauer C; Pollard J; Watters J; Garcia-Echeverria C; Wiederschain D; Adrian F; Zhang J
    Oncotarget; 2014 May; 5(10):3362-74. PubMed ID: 24830942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.
    Weinberg LR; Albom MS; Angeles TS; Breslin HJ; Gingrich DE; Huang Z; Lisko JG; Mason JL; Milkiewicz KL; Thieu TV; Underiner TL; Wells GJ; Wells-Knecht KJ; Dorsey BD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7325-30. PubMed ID: 22041060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
    Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
    Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
    Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
    J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
    Dugan BJ; Gingrich DE; Mesaros EF; Milkiewicz KL; Curry MA; Zulli AL; Dobrzanski P; Serdikoff C; Jan M; Angeles TS; Albom MS; Mason JL; Aimone LD; Meyer SL; Huang Z; Wells-Knecht KJ; Ator MA; Ruggeri BA; Dorsey BD
    J Med Chem; 2012 Jun; 55(11):5243-54. PubMed ID: 22594690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel indole-3-propanamide exerts its immunosuppressive activity by inhibiting JAK3 in T cells.
    Carbonnelle D; Duflos M; Marchand P; Chauvet C; Petit JY; Lang F
    J Pharmacol Exp Ther; 2009 Nov; 331(2):710-6. PubMed ID: 19710367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors.
    Yang SH; Khadka DB; Cho SH; Ju HK; Lee KY; Han HJ; Lee KT; Cho WJ
    Bioorg Med Chem; 2011 Jan; 19(2):968-77. PubMed ID: 21185195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.